Integra LifeSciences Holdings Corporation

NasdaqGS:IART Stock Report

Market Cap: US$2.7b

Integra LifeSciences Holdings Valuation

Is IART undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IART when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: IART ($34.83) is trading below our estimate of fair value ($76.91)

Significantly Below Fair Value: IART is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for IART?

Other financial metrics that can be useful for relative valuation.

IART key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.7x
Enterprise Value/EBITDA10.7x
PEG Ratio1.1x

Price to Earnings Ratio vs Peers

How does IART's PE Ratio compare to its peers?

The above table shows the PE ratio for IART vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average81.4x
LIVN LivaNova
171.8x40.2%US$3.0b
NUVA NuVasive
73.3x46.2%US$2.1b
CNMD CONMED
38.3x31.1%US$2.5b
ITGR Integer Holdings
42.4x21.6%US$3.8b
IART Integra LifeSciences Holdings
40.2x38.1%US$2.7b

Price-To-Earnings vs Peers: IART is good value based on its Price-To-Earnings Ratio (40.2x) compared to the peer average (84.2x).


Price to Earnings Ratio vs Industry

How does IART's PE Ratio compare vs other companies in the US Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.1%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.1%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: IART is expensive based on its Price-To-Earnings Ratio (40.2x) compared to the US Medical Equipment industry average (39.6x).


Price to Earnings Ratio vs Fair Ratio

What is IART's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IART PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio40.2x
Fair PE Ratio43x

Price-To-Earnings vs Fair Ratio: IART is good value based on its Price-To-Earnings Ratio (40.2x) compared to the estimated Fair Price-To-Earnings Ratio (43x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IART forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$34.83
US$44.80
+28.6%
14.3%US$57.00US$37.00n/a10
Mar ’25US$35.99
US$44.80
+24.5%
14.3%US$57.00US$37.00n/a10
Feb ’25US$40.92
US$46.60
+13.9%
14.5%US$57.00US$37.00n/a10
Jan ’25US$43.55
US$46.10
+5.9%
15.3%US$57.00US$37.00n/a10
Dec ’24US$41.02
US$43.27
+5.5%
14.9%US$55.00US$36.00n/a11
Nov ’24US$36.85
US$42.60
+15.6%
15.0%US$55.00US$36.00n/a10
Oct ’24US$38.19
US$47.20
+23.6%
12.9%US$60.00US$39.00n/a10
Sep ’24US$42.76
US$47.20
+10.4%
12.9%US$60.00US$39.00n/a10
Aug ’24US$44.95
US$47.20
+5.0%
12.9%US$60.00US$39.00n/a10
Jul ’24US$41.13
US$47.90
+16.5%
16.2%US$65.00US$39.00n/a10
Jun ’24US$38.42
US$49.00
+27.5%
16.1%US$65.00US$39.00n/a10
May ’24US$55.63
US$57.80
+3.9%
8.3%US$66.00US$50.00n/a10
Apr ’24US$57.41
US$59.00
+2.8%
11.5%US$75.00US$50.00n/a10
Mar ’24US$54.82
US$59.00
+7.6%
11.5%US$75.00US$50.00US$35.9910
Feb ’24US$58.57
US$58.40
-0.3%
12.4%US$75.00US$50.00US$40.9210
Jan ’24US$56.07
US$56.90
+1.5%
13.8%US$75.00US$50.00US$43.5510
Dec ’23US$56.36
US$54.50
-3.3%
15.3%US$75.00US$48.00US$41.0210
Nov ’23US$50.95
US$54.50
+7.0%
15.3%US$75.00US$48.00US$36.8510
Oct ’23US$42.36
US$62.44
+47.4%
15.2%US$85.00US$50.00US$38.199
Sep ’23US$47.48
US$62.44
+31.5%
15.2%US$85.00US$50.00US$42.769
Aug ’23US$56.87
US$63.44
+11.6%
13.6%US$85.00US$55.00US$44.959
Jul ’23US$55.00
US$71.75
+30.5%
9.6%US$85.00US$65.00US$41.138
Jun ’23US$60.85
US$71.75
+17.9%
9.6%US$85.00US$65.00US$38.428
May ’23US$61.16
US$73.60
+20.3%
9.1%US$85.00US$65.00US$55.6310
Apr ’23US$66.52
US$74.18
+11.5%
8.2%US$85.00US$65.00US$57.4111
Mar ’23US$66.32
US$74.18
+11.9%
8.2%US$85.00US$65.00US$54.8211

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.